Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RDY
stocks logo

RDY

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
84.67B
+1.29%
18.311
+15.71%
Estimates Revision
The market is revising Downward the revenue expectations for Dr. Reddy's Laboratories Limited (RDY) for FY2026, with the revenue forecasts being adjusted by -0.5% over the past three months. During the same period, the stock price has changed by -0.07%.
Revenue Estimates for FY2026
Revise Downward
down Image
-0.5%
In Past 3 Month
EPS Estimates for FY2026
Revise Downward
down Image
-3.7%
In Past 3 Month
Stock Price
Go Down
down Image
-0.07%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Dr Reddy's Laboratories Ltd (RDY.N) is 21.07, compared to its 5-year average forward P/E of 20.44. For a more detailed relative valuation and DCF analysis to assess Dr Reddy's Laboratories Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
20.44
Current PE
21.07
Overvalued PE
24.61
Undervalued PE
16.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
12.52
Current EV/EBITDA
13.34
Overvalued EV/EBITDA
14.82
Undervalued EV/EBITDA
10.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
3.22
Current PS
3.08
Overvalued PS
3.59
Undervalued PS
2.84
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

RDY News & Events

Events Timeline

(ET)
2025-10-03
08:01:54
Esperion and Dr. Reddy's Reach Settlement Agreement Regarding ANDA Filing
select
2025-09-22 (ET)
2025-09-22
06:19:12
Alvotech announces favorable CHMP opinion for AVT03
select
2025-08-18 (ET)
2025-08-18
08:20:37
Dr. Reddy's and Extrovis Introduce Authorized Generic of CARAC in the U.S.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
11-01NASDAQ.COM
Dr. Reddy's Laboratories Hits Oversold Status (RDY)

  • Dr. Reddy's Laboratories Oversold Status: Shares of Dr. Reddy's Laboratories Ltd. (RDY) have entered oversold territory with an RSI reading of 29.9, indicating potential exhaustion of recent selling pressure.

  • Current Share Performance: The stock traded as low as $13.20 per share, with a recent price of $13.29, compared to its 52-week low of $12.26 and high of $16.17.

  • Comparison with S&P 500 ETF: The current RSI for the S&P 500 ETF (SPY) is 63.0, highlighting a significant difference in market momentum between RDY and the broader market.

  • Investment Opportunity: Bullish investors may view the low RSI reading as a potential entry point for buying shares of RDY as selling pressure may be waning.

[object Object]
Preview
9.5
10-25NASDAQ.COM
Dr. Reddy's Laboratories Sees Increase in Q2 Profit

  • Quarterly Profit Increase: Dr. Reddy's Laboratories reported a second quarter profit of INR 14.37 billion, up from INR 12.55 billion in the previous year, translating to INR 17.25 per share compared to INR 15.05 per share.

  • Revenue Growth: The company's revenues rose to INR 88.05 billion from INR 80.162 billion, driven by growth in key markets despite challenges in the North America Generics segment.

  • Market Challenges: The North America Generics segment experienced price erosion in certain products and a decline in lenalidomide sales, impacting overall performance.

  • Positive Contributions: The recently acquired Consumer Healthcare portfolio, particularly in Nicotine Replacement Therapy (NRT), positively influenced the company's overall performance.

[object Object]
Preview
9.0
10-23Newsfilter
Aurigene Oncology to Present Cutting-Edge A-PROX Platform at the 2025 AACR-NCI-EORTC International Conference

  • Aurigene's Conference Presentation: Aurigene Oncology Limited will present new data from its Targeted Protein Degradation (TPD) and Proximity Inducer Platform (A-PROX) at the AACR-NCI-EORTC conference in Boston from October 22-26, 2025, showcasing advancements in cancer therapies.

  • Innovative Drug Development: The A-PROX platform has led to a pre-clinical portfolio of next-generation degraders, including a recently FDA-approved SMARCA2-selective degrader, which targets previously undruggable pathways in oncology.

  • Key Poster Presentations: Aurigene will feature several poster presentations, including an orally bioavailable SMARCA2 degrader and a first-in-class anti-SIRPα/β dual antibody, highlighting their innovative approaches to cancer treatment.

  • Company Background: Aurigene, a subsidiary of Dr. Reddy's Laboratories, has been active since 2001 in developing novel cancer therapeutics, with a pipeline that includes both clinical and pre-clinical candidates targeting various oncological pathways.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Dr Reddy's Laboratories Ltd (RDY) stock price today?

The current price of RDY is 14.14 USD — it has increased 0.07 % in the last trading day.

arrow icon

What is Dr Reddy's Laboratories Ltd (RDY)'s business?

Dr. Reddy’s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.

arrow icon

What is the price predicton of RDY Stock?

Wall Street analysts forecast RDY stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RDY is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Dr Reddy's Laboratories Ltd (RDY)'s revenue for the last quarter?

Dr Reddy's Laboratories Ltd revenue for the last quarter amounts to 1.01B USD, increased 5.41 % YoY.

arrow icon

What is Dr Reddy's Laboratories Ltd (RDY)'s earnings per share (EPS) for the last quarter?

Dr Reddy's Laboratories Ltd. EPS for the last quarter amounts to 0.20 USD, increased 11.11 % YoY.

arrow icon

What changes have occurred in the market's expectations for Dr Reddy's Laboratories Ltd (RDY)'s fundamentals?

The market is revising Downward the revenue expectations for Dr. Reddy's Laboratories Limited (RDY) for FY2026, with the revenue forecasts being adjusted by -0.5% over the past three months. During the same period, the stock price has changed by -0.07%.
arrow icon

How many employees does Dr Reddy's Laboratories Ltd (RDY). have?

Dr Reddy's Laboratories Ltd (RDY) has 27811 emplpoyees as of December 05 2025.

arrow icon

What is Dr Reddy's Laboratories Ltd (RDY) market cap?

Today RDY has the market capitalization of 11.77B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free